Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN- 207 inhibits the growth of PC-82 human prostate cancer in nude mice

Prostate

Volumn 38, Issue 2, 1999, Pages 151-158

  Koppán, Miklos ^a,b   Nagy, Attila ^a,b   Schally, Andrew V ^a,b   Plonowski, Artur ^a,b   Halmos, Gábor ^a,b   Arencibia, José M ^a,b   Groot, Kate ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 pyrrolinodoxorubicin; LH RH receptor; PC 82 tumor; Prostate cancer; Targeted chemotherapy

Indexed keywords

2 PYRROLINODOXORUBICIN; CYTOTOXIC AGENT; DRUG CARRIER; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CANCER HORMONE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0032949187     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(19990201)38:2<151::aid-pros9>3.0.co;2-%23     Document Type: Article

References (23)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA 1998;48:6-29.
2. Schroeder FH, Boyle P. Screening of prostate cancer - necessity or nonsense? Eur J Cancer 1993;29:656-661.
3. Crawford ED. Hormonal therapy of prostatic carcinoma. Defining the challenge. Cancer [Suppl] 1990;66:1035-1038.
4. Sogani PC, Fair WR. Treatment of advanced prostatic cancer. Urol Clin North Am 1987;14:353-371.
5. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E III, Bast RC Jr, Kufe DE, Morton DL, Weichselbaum RR, editors. Cancer medicine, 4th ed. Baltimore: Williams and Wilkins; 1997. p 1067-1086.
6. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 1988;15:371-389.
7. Rangel C, Matzkin H, Soloway MS. Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 1992;39:577-582.
8. Fekete M, Redding TW, Comaru-Schally AM, Pontes AE, Connelly RW, Srkalovic G, Schally AV. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin and epidermal growth factor in rat and human prostate cancers and in benign prostatic hyperplasia. Prostate 1989;14:191-208.
9. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer 1990;62:96-99.
10. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P, Miyazaki M, Comaru-Schally AM, Yano T, Emons G. LH-RH analogs with cytotoxic radicals. In: Filicori M, Flamigni C, editors. Treatment with GnRH analogs: controversies and perspectives. Camforth: Parthenon; 1996. p 33-44.
11. Nagy A, Armatis P, Schally AV. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 1996;93:2464-2469.
12. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A, Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93: 7269-7273.
13. Hoehn W, Schroeder FH, Riemann JF, Joebsis AC, Hermanek P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate 1980;1: 95-104.
14. van Steenbrugge GJ, Schroeder FH. Characterization and application of PC-82, a hormone-dependent, transplantable tumor line, derived from a human prostatic adenocarcinoma. In: Bresciani F, editor. Progress in cancer research and therapy. New York: Raven Press; 1984. p 453-465.
15. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 1992;52:2538-2544.
16. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA 1989;86: 6318-6322.
17. Halmos G, Schally AV, Pinski J, Buenfil MV, Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist cetrorelix. Proc Natl Acad Sci USA 1996;93:2398-2402.
18. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220-239.
19. Lamharzi N, Halmos G, Armatis P, Schally AV. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 1998;12:671-675.
20. Steel RGD, Torrie J. Principles and procedures of statistics. New York: McGraw-Hill; 1976. 114 p.
21. Kovacs M, Schally AV, Nagy A, Koppan M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1997;94:1420-1425.
22. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. JNCI 1997;89:1803-1809.
23. Jungwirth A, Schally AV, Nagy A, Pinski J, Groot K, Galvan G, Szepeshazi K, Halmos G. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 1997;10:877-884.